First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia

CAR T cells have shown clinical efficacy for acute lymphoblastic leukemia, but this therapy has not been effective for acute myeloid leukemia (AML), and other treatment options are needed. Theoretically, CAR-NK cells have a more favorable toxicity profile compared to CAR T cells, especially in avoid...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Am J Cancer Res
Auteurs principaux: Tang, Xiaowen, Yang, Lin, Li, Zheng, Nalin, Ansel P, Dai, Haiping, Xu, Ting, Yin, Jia, You, Fengtao, Zhu, Mingqing, Shen, Wenhong, Chen, Guanghua, Zhu, Xiaming, Wu, Depei, Yu, Jianhua
Format: Artigo
Langue:Inglês
Publié: e-Century Publishing Corporation 2018
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6048396/
https://ncbi.nlm.nih.gov/pubmed/30034945
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires